Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1978000005) MAGNETIC POLYMER PARTICLES
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. Magnetic polymer particles as carriers of biologically, preferably pharmaceutically active substance, characterized in that they comprise particles of a preferably porous polymer in the pores or lattice of which there is deposited magnetic material, said biologically active substance being associated with the polymer particles.
2. Magnetic polymer particles as claimed in claim 1, characterized in that the biologically active substance is an enzyme inhibitor, an enzyme, preferably a proteolytic enzyme, a cytostaticum, a radio nucleotid, insulin . or steroid.
3. Magnetic polymer particles as claimed in claim 1, characterized in that the polymer is a polysaccharide, preferably agarose or starch, and/or an acrylic polymer.
4. Magnetic polymer particles as claimed in any of claims 1 to 3, characterized in that the magnetic material is particulate or colloidal, preferably colloidal ferrite.
5. A process for production of magnetic polymer par-tides as carriers of biologically, preferably pharmaceutically active substance, characterized in that porous polymer particles which may carry the biologically active substance, and/or polymerizable monomers are contacted with a colloidal solution of a magnetic material and op-tionally biologically active substance, the optionally present monomers are polymerized, the solvent is optionally removed, the magnetic material and the optionally present biologically active substance being deposited in the pores or lattice of the polymer particles , whereupon the resul-ting magnetic polymer particles are associated with the biologically active substance unless said substance is already associated with the polymer particles.
6. A process as claimed in claim 5, characterized in that there is associated with the magnetic polymer partic- les as biologically active substance an enzyme inhibitor, an enzyme, preferably a proteolytic enzyme, a cytostaticum, a nucleotid, insulin or a steroid.
7. A process as claimed in claim 5, characterized in that as polymer particles use is made of particles of a polysaccharide, preferably agarose or starch, and/or an acrylic polymer.
8. A process as claimed in claim 5, characterized in that an acrylic monomer is inserted as polymerizable mono-mer.
9. A process as claimed in any of claims 5-8, characterized in that colloidal ferrite is used as magnetic material.
10. Use of the magnetic polymer particles claimed in claim 1, as carriers of biologically, preferably pharmaceutically active substance, characterized in that the substance is associated with particles of a preferably porous polymer, preferably a polysaccharide, such as agarose or starch, or an acrylic polymer, which particles are given magnetic properties by incorporation of a magnetic material in the form of particles or a colloidal solution.
11. A method of retaining a biologically, preferably pharmaceutically active substance within a restricted area, characterized in that the substance is associated with a carrier in the form of preferably porous polymer particles which are given magnetic properties by incorporation of a magnetic material in the form of particles or a colloidal solution, whereupon the magnetic polymer particles with the substance associated therewith is retained within the restricted area by the application of a magnetic field.
12. A method of treating a diseased tissue, characterized in that an effective amount of a pharmaceutically active substance is concentrated in the tissue by supply of the substance to the tissue associated with a carrier in the form of preferably porous polymer particles which have been given magnetic properties by incorporation of a magnetic material in the form of particles or a collo- idal solution, and that the magnetic carrier with the associated pharmaceutical substance is concentrated to the diseased tissue by the application of a magnetic field.

AMENDED CLAIMS
(received by the International Bureau on 4 October 1978 (04.10.78))

1. Magnetic polymer particles as carriers of biologically, preferably pharmaceutically active substance, characterized in that they comprises particles of a preferably porous polymer in the pores or lattice of which there is deposited magnetic material, said biologically active substance being associated with the polymer particles.
2. Magnetic polymer particles as claimed in claim 1, characterized in that the biologically active substance is chosen from the group consisting of an enzyme inhibitor, an enzyme, such as a proteolytic enzyme, a cyto-staticum, a radio nucleotid, insulin, a steroid and a live microbe.
3. Magnetic polymer particles as claimed in claim 1, characterized in that the polymer is chosen from the group consisting of an acrylic polymer, red corpuscles, a liposome and a polysacharide , such as agarose or starch.

4. Magnetic polymer particles as claimed in any of claims 1 to 3 , characterized in that the magnetic material is particulate or colloidal, preferably colloidal ferrite.

5. A process for production of magnetic polymer particles as carriers of biologically, preferably pharmaceutically active substance, characterized in that porous polymer particles which may carry the biologically active substance, and/or polymerizable monomers are contacted with a colloidal solution of a magnetic material and optionally biologically active substance, the optionally present monomers are polymerized, the solvent is optionally removed, the magnetic material and the optionally present biologically active substance being deposited in the pores or lattice of the polymer particles , whereupon the resulting magnetic polymer particles are associated with the biologically active substance unless said substance is already associated with the polymer particles.

6. A process as claimed in claim 5, characterized in that there is associated with the magnetic polymer particles as biologically active substance a substance chosen from the group consisting of an enzyme inhibitor, an en-zyme, such as a proteolytic enzyme, a cytostaticum, a nucleotid, insulin, a steroid, and a live microbe.
7. A process as claimed in claim 5, characterized in that as polymer particles use is made of particles chosen from the group consisting of red corpuscles, particles of a liposome, an acrylic polymer and a polysaccharide, such as agarose or starch.
8. A process as claimed in claim 5, characterized in that an acrylic monomer is inserted as polymerizable monomer.
9. A process as claimed in any of claims 5-8, characterized in that colloidal ferrite is used as magnetic material.
10. Use of the magnetic polymer particles claimed in claim 1, as carriers of biologically, preferably pharma-ceutically active substance, characterized in that the substance is associated with particles of a preferably porous polymer, preferably a polysaccharide, such as agarose or starch, or an acrylic polymer, which particles are given magnetic properties by incorporation of a magnetic mate-rial in the form of particles or a colloidal solution.
11. A method of retaining a biologically, preferably pharmaceutically active substance within a restricted area, characterized in that the substance is associated with a carrier in the form of preferably porous polymer particles which are given magnetic properties by incorporation of a magnetic material in the form of particles or a colloidal solution, whereupon the magnetic polymer particles with the substance associated therewith is retained within the restricted area by the application of a magnetic field.
12. A method of treating a diseased tissue, characterized in that an effective amount of a pharmaceutically active substance is concentrated in the tissue by supply of the substance to the tissue associated with a carrier in the form of preferably porous polymer particles which have been given magnetic properties by incorporation of a magnetic material in the form of particles or a collo-idal solution, and that the magnetic carrier with the associated pharmaceutical substance is concentrated to the diseased tissue by the application of a magnetic field.

STATEMENT UNDER ARTICLE 19

New pages 9-11 with amended claims 2, 3, 6 and 7 are filed.

In claims 2 and 6 the list of possible biologically active substances has been extended by the addition of a live microbe as a further substance. A base for this amendment is to be found in the specification on page 7, lines 2—6. Also the expression "chosen from the group consisting of" has been introduced after "is" on page 9, line lO of the original claim 2 and the expression "a substance chosen from the group consisting of" has been introduced after "substance" in claim 6, page lO, line 1.

In claims 3 and 7 the list of possible polymers has been extended by the addition of red corpuscles and a liposome as polymers. Also the order of entrance on the list of possible polymers has been changed somewhat. A base for this amendment is to be found in the specification on page 7, lines 7-14. Further, in claim 3 there has been added after "is" on page 9, line 14 of original claim 3 the expression "chosen from the group consisting of". In claim 7 the corresponding amendment has been made.

In all of the claims 2, 3, 6 and 7 "such as" has been substituted for "preferably" .